
Donald A. Richards, MD, PhD, discusses the use of genetic testing in patients with metastatic pancreatic cancer.

Your AI-Trained Oncology Knowledge Connection!


Donald A. Richards, MD, PhD, discusses the use of genetic testing in patients with metastatic pancreatic cancer.

Donald A. Richards, MD, PhD, discusses the secondary endpoints of the randomized, double-blind, phase III POLO trial, which evaluated maintenance therapy with olaparib in patients with germline BRCA-mutated, metastatic pancreatic cancer.

Donald A. Richards, MD, PhD, discusses the potential benefits of PARP inhibitors in patients with metastatic pancreatic cancer who harbor somatic mutations.

Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses the design and findings of the phase III POLO trial in patients with pancreatic cancer.

Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses PARP inhibition in patients with pancreatic cancer.

Published: September 19th 2019 | Updated:

Published: September 21st 2019 | Updated:

Published: September 23rd 2019 | Updated:

Published: September 27th 2019 | Updated:

Published: October 21st 2019 | Updated: